Pub-2005

Articles

Title
A SCID-hu in vivo model of human Waldenström macroglobulinemia
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia
CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia
Diagnosis and management of Waldenstrom's macroglobulinemia
Extended rituximab therapy in Waldenström's macroglobulinemia
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia